Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $36 from $34 and keeps a Buy rating on the shares. The firm anticipates calendar year 2025 to “represent an important year on the execution front for NX-5948,” with data updates in chronic lymphocytic leukemia and non-Hodgkin lymphoma, complemented by the initiation of both multiple registrational trials in CLL, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX: